Medtronic CoreValve Evolut 23mm receives CE Mark

Medtronic has received European CE Mark approval for its innovative new cardiovascular valve system CoreValve Evolut 23mm.

This latest addition to the company's self-expanding transcatheter aortic valve implantation (TAVI) portfolio incorporates technology that optimises fit, thus helping to strengthen the seal between the prosthetic and native valves.

Following the introduction of this device, the company can now claim to offer the broadest range of TAVI patient valve sizes, with annulus diameters ranging from 18mm to 29mm.

The Medtronic CoreValve System was originally awarded CE Mark approval in 2007 and has now been implanted in more than 30,000 patients outside of the US.

Professor Eberhard Grube from the University Hospital Bonn said: "The CoreValve System has been successfully implanted in tens of thousands of patients worldwide and this new valve builds on that experience."

Last week, the company announced the commencement of patient enrolment for a clinical trial assessing the impact of physician-led improvement initiatives on the treatment of heart rhythm abnormalities.